

Annals of Nanomedicine and Nanotechnology

Review Article

Impact of nanorobotic drug delivery on Quality of Life in Patients with solid tumors

Zhang X^{1*}, Liu J² and Huang H³

¹Department of Nanomedicine, Narmada Center for Nanomedicine, China

²Department of Nanomedicine, Godavari Center for Nanomedicine, Vietnam

³Division of Nanotechnology, Ganges Academy of Nanomedicine, Thailand

*Address for Correspondence: Xiu Zhang, Department of Nanomedicine, Narmada Center for Nanomedicine, China; E-mail: xiu.zhang@narmada.edu

Received: 25 July 2025; Accepted: 14 October 2025; Published: 14 January 2026.

Citation of this article: Zhang X, Liu J, Huang H (2026) Impact of nanorobotic drug delivery on Quality of Life in Patients with solid tumors. Ann Nanomed Nanotechnol, 8(1): 01-06. DOI: [10.5281/zenodo.22812126](https://doi.org/10.5281/zenodo.22812126)

Copyright: © 2026 Xiu Zhang, et al. This is an open access article distributed under the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Conventional chemotherapy distributes throughout the body largely independent of tumor location, producing systemic toxicity that instruments such as the QLQ-C30 and FACT-G were built to quantify as patient-reported quality of life [1,2].

Objective: This review synthesizes evidence on how nanoparticle and early nanorobotic drug delivery reshape quality of life in solid tumors, from measurement instruments through biodistribution rationale to trial evidence.

Methods: We conducted a narrative synthesis of psychometric validation studies, randomized trials comparing nanoparticle formulations with conventional chemotherapy, a pooled toxicity meta-analysis, and mechanistic reviews of nanoparticle and nanorobotic delivery.

Findings: Pegylated liposomal doxorubicin cut cardiac toxicity to roughly 7% against roughly 26% with conventional doxorubicin at comparable efficacy [12]; nab-paclitaxel eliminated solvent-related hypersensitivity while improving response rate [16]; and a pooled analysis found lower grade 3 or higher hematologic toxicity and neuropathy with nanoparticle chemotherapy [20], while nanorobotic platforms remain largely preclinical [5,6].

Conclusions: Nanoparticle delivery improves quality of life in solid tumors chiefly by reducing or redistributing systemic toxicity rather than by uniformly improving tumor control, and emerging nanorobotic trials should build validated quality-of-life endpoints in directly [7,24].

Keywords: nanorobotic drug delivery; quality of life; solid tumors; nanoparticle chemotherapy; cancer toxicity

1. Introduction

Cytotoxic chemotherapy has always bought its tumor response with a tax on the rest of the body. Conventional small-molecule cytotoxics distribute wherever blood flow carries them, so a dose large enough to kill dividing tumor cells is also large enough to damage marrow, gut epithelium, peripheral nerves, and, for anthracyclines, the myocardium. Patient-reported quality of life, once a soft secondary endpoint, is now central to how oncology trials are read, largely because instruments such as the EORTC QLQ-C30 and the Functional Assessment of Cancer Therapy scale gave that experience a quantitative, trial-ready form [1,2].

Nanoscale drug carriers were conceived to change this arithmetic without abandoning cytotoxic payloads that already work. Encapsulating a drug in a liposome, an albumin-bound particle, a polymeric micelle, or a more actively steered nanorobotic platform is meant to lengthen circulation time and exploit the leaky vasculature many solid tumors display, raising the fraction of dose reaching tumor tissue relative to healthy organs [3,4]. When passive enhanced permeability and retention is combined with surface ligands or the control loops implied by "nanorobotic," the carrier's distribution becomes, in principle, actively steerable [5,6]. The clinical promise is not primarily a larger tumor response but a materially different toxicity and symptom profile, and it is that link this review is built around.

The evidence base is two decades deep for early liposomal and albumin-bound platforms and considerably thinner for actively targeted and robotic systems. This review synthesizes what randomized trials, cohorts, and pooled analyses show about how nanoparticle and early nanorobotic delivery reshape quality of life in solid tumors, moving from the instruments used to measure that experience, through the mechanistic case for reduced toxicity, to the trial evidence in breast, ovarian, and pancreatic cancer.

2. Methods

We conducted a narrative synthesis of peer-reviewed literature on nanoparticle and nanorobotic drug delivery and its relationship to patient-reported quality of life and toxicity in solid tumors. Sources were prioritized in three tiers: the psychometric literature validating the EORTC QLQ-C30, FACT-G, and EQ-5D-5L; randomized phase III trials and cohorts comparing a nanoparticle formulation against its conventional counterpart in breast, ovarian, or pancreatic cancer with reported toxicity or quality-of-life outcomes; and mechanistic reviews of the enhanced-permeability-and-retention rationale and of emerging nanorobotic delivery. We included a pooled meta-analysis of grade 3 or higher adverse events across nanoparticle versus conventional chemotherapy trials, since no single trial here was powered around toxicity as a primary endpoint. Pharmacokinetic or biodistribution studies without toxicity or quality-of-life data were used only for mechanistic framing.

3. Quality-of-life measurement in nanomedicine oncology trials

Every comparative claim below rests on a handful of instruments. The EORTC QLQ-C30 combines a global health scale with functional subscales for physical, role, emotional, cognitive, and social functioning and symptom scales for fatigue, nausea, and pain, built for use across tumor types rather than one disease [1]. Cella and colleagues' FACT-G weights physical, social, emotional, and functional well-being and supports disease-specific modules built since for breast, ovarian, and pancreatic cancer [2]. The EQ-5D-5L, in the five-level form validated by Herdman and colleagues, trades disease specificity for a compact health-utility index that feeds directly into quality-adjusted life-year calculations [7].

None of these instruments measures nanoparticle exposure directly; they measure the downstream consequence, symptom burden and functional capacity, that altered drug distribution is hypothesized to improve.

A platform that reduces grade 3 neutropenia or eliminates hypersensitivity reactions should register on the fatigue, physical functioning, or global health subscales, and that link is what the trials below test.

4. Toxicity reduction as the mechanistic route to preserved quality of life

The mechanistic case runs through altered biodistribution, not through any change to the cytotoxic mechanism itself. Peer and colleagues frame the nanocarrier's job as threefold: extend circulation time enough to accumulate passively via enhanced permeability and retention, reduce peak free-drug exposure in healthy organs, and, where ligands are added, layer active targeting on top [3]. Golombek and colleagues' more recent appraisal is more circumspect, showing leaky-vasculature accumulation varies enormously across and within tumors, one reason the toxicity benefit of nanoformulation has proven far more consistent than any efficacy advantage [4]. Sindhwani and colleagues' imaging study reinforces this, finding active transendothelial transport, not passive leakiness, accounts for most particle entry in their models [8]. Shi and colleagues make the field-level version of the same point: platforms that reached and stayed in oncology practice are almost uniformly ones whose demonstrated advantage was tolerability rather than a transformed response rate [9], and Wicki and colleagues' review catalogs the same pattern across the platforms discussed below [10].

Table 1 summarizes the toxicity and quality-of-life signal across the pivotal comparative trials this review draws on. The pattern that recurs is not superior tumor control, more often comparable than clearly superior, but a materially different and generally more tolerable toxicity profile, the outcome altered biodistribution would predict (Table 1).

5. Cardiotoxicity and skin toxicity in pegylated liposomal doxorubicin

Pegylated liposomal doxorubicin is the clearest

single-agent case study because its comparator, conventional doxorubicin, carries a well-characterized, dose-limiting toxicity the reformulation was designed to avoid. Barenholz's account of Doxil's development explains the logic: PEGylation extends circulation half-life dramatically, and because free drug reaches the myocardium far less readily when retained inside a long-circulating liposome, cardiotoxicity limiting cumulative anthracycline dosing should fall [11]. O'Brien and colleagues tested this directly against conventional doxorubicin in metastatic breast cancer and found cardiac toxicity in roughly a quarter of patients on conventional doxorubicin against well under one in ten on the liposomal formulation, with broadly comparable time to progression and response [12] (Figure 1). Safra and colleagues showed a complementary result, reporting clinical cardiotoxicity remained rare even at cumulative liposomal doses of 500 mg/m2 or more, an exposure expected to produce substantial cardiac injury with the conventional formulation [13].

Table 1: Toxicity and quality-of-life signal across pivotal comparative trials of nanoparticle versus conventional chemotherapy in solid tumors [12,16,18,19,20].			
Trial / analysis	Tumor type	Nanoparticle agent vs comparator	Key toxicity / quality-of-life signal
[12]	Metastatic breast cancer	Pegylated liposomal doxorubicin vs conventional doxorubicin	Cardiac toxicity ~7% vs ~26%; comparable efficacy
[16]	Metastatic breast cancer	Nab-paclitaxel vs solvent-based paclitaxel	Higher response rate; no premedication needed; solvent-hypersensitivity eliminated
[18]; [19]	Metastatic pancreatic cancer	Nab-paclitaxel+gemcitabine; nanoliposomal irinotecan+5-FU/LV	Survival benefit with manageable, clinically tolerable toxicity
[20]	Pooled solid tumors	Nanoparticle chemotherapy vs conventional chemotherapy (meta-analysis)	Lower grade ≥3 hematologic toxicity and peripheral neuropathy; slightly more infusion reactions




Figure 1: Protocol-defined cardiac toxicity in a randomized phase III trial of pegylated liposomal doxorubicin versus conventional doxorubicin for metastatic breast cancer, roughly 7% with the liposomal formulation against roughly 26% with conventional doxorubicin, at broadly comparable time to progression and overall response between arms [12].

This cardioprotection is only half the story. Gordon and colleagues' randomized comparison against topotecan in recurrent ovarian carcinoma found similar survival but a distinctly different adverse-event pattern: less severe myelosuppression but a recognizable rate of palmar-plantar erythrodysesthesia and mucocutaneous toxicity with the liposomal arm [14]. Krown and colleagues' review of liposomal anthracyclines in Kaposi's sarcoma, where the formulation became standard specifically for its tolerability advantage in an already immunocompromised population, makes the same point differently: the quality-of-life gain is real but comes bundled with a distinct toxicity signature that must be weighed against the toxicity it replaces, not assumed a net-neutral swap [15].

6. Nab-paclitaxel, polymeric micelles, and nanoliposomal irinotecan

Albumin-bound and polymeric-micelle platforms extend the same logic to a different toxicity problem: the solvent, not only the payload, that conventional taxane formulations require. Gradishar and colleagues' phase III trial of nab-paclitaxel against solvent-based paclitaxel in metastatic breast cancer found a significantly higher response rate, delivered without the premedication solvent-based paclitaxel requires against Cremophor EL hypersensitivity, since the albumin-bound particle has no

such solvent [16]. Kim and colleagues' earlier study of Genexol-PM, a Cremophor-free polymeric micelle paclitaxel, reported a similarly favorable tolerability profile, reinforcing that eliminating the solvent vehicle removes a category of morbidity unrelated to tumor biology [17].




Figure 2: Pooled grade 3 or higher hematologic toxicity and peripheral neuropathy incidence for nanoparticle-based versus conventional chemotherapy across multiple solid-tumor trials, drawn from a recent meta-analysis [20].

In pancreatic cancer, two nanoparticle formulations changed practice from opposite ends of the disease course: Von Hoff and colleagues' nab-paclitaxel plus gemcitabine showed a survival benefit with manageable toxicity that supported first-line adoption [18], and Wang-Gillam and colleagues' NAPOLI-1 trial showed nanoliposomal irinotecan with fluorouracil and folinic acid extended second-line survival after gemcitabine failure, again with tolerable toxicity [19].

Because none of these trials was powered around a symptom-burden endpoint, the clearest quantitative toxicity signal comes from a pooled analysis rather than any single trial. Kanwar and colleagues' meta-analysis of nanoparticle against conventional chemotherapy across solid-tumor trials reported lower grade 3 or higher hematologic toxicity, roughly 30% against roughly 34%, and lower peripheral neuropathy, roughly 17% against roughly 26%, though infusion-related reactions ran somewhat higher with nanoparticle chemotherapy [20] (Figure 2). Bobo and colleagues' survey of FDA-approved nanoparticle medicines and Anselmo and Mitragotri's

paired reviews track how these platforms moved from pivotal trials to broader practice without displacing conventional chemotherapy outright where both remain options [21,22,23].

7. Nanorobotic and actively targeted delivery: extending the rationale

The platforms above are mechanistically passive or semi-passive, relying on circulation time and leaky vasculature rather than onboard navigation. "Nanorobotic" delivery describes a further step in which surface engineering, external magnetic or acoustic fields, or biohybrid propulsion actively steer a carrier toward tumor tissue. Cavalcanti and Freitas's early control-theoretic framework treated cooperating nanorobotic agents as a controllable swarm rather than a passively distributed dose, an idea still substantially ahead of any clinical toxicity or quality-of-life data [5]. Erkoc and colleagues' review of mobile microrobots catalogs chemically propelled, magnetically actuated, and biohybrid designs now in preclinical development, and is candid that the gap between demonstrated in vivo navigation and any powered patient-reported outcome trial remains substantial [6].

Van der Meel and colleagues' concept of "smart" cancer nanomedicine bridges this gap conceptually, describing environment-responsive and actively targeted systems as the logical next generation beyond the passive platforms summarized above [24]. The honest position is that the quality-of-life case for nanorobotic delivery in solid tumors currently rests on extrapolation from passive and semi-active platforms with randomized data, combined with a still-preclinical engineering literature, rather than on any nanorobotic platform that has itself completed a comparative quality-of-life trial.

8. Discussion

Together, these trials support a specific claim: nanoparticle drug delivery in solid tumors improves quality of life primarily by reducing or redistributing

systemic toxicity, not by producing uniformly larger tumor responses. The cardioprotection of pegylated liposomal doxorubicin, the elimination of solvent-related hypersensitivity with albumin-bound and polymeric-micelle paclitaxel, and the pooled reduction in grade 3 or higher hematologic toxicity and neuropathy across nanoparticle chemotherapies all point toward the same mechanism, altered biodistribution lowering peak exposure in toxicity-limiting organs, rather than a uniform efficacy advantage [12,16,20]. That is a meaningful benefit in its own right: for a patient whose disease is unlikely to be cured, comparable disease control with materially less fatigue, febrile-neutropenia risk, or irreversible cardiac injury is a genuine improvement independent of survival.

The evidence has real limits. Few pivotal trials used a validated quality-of-life instrument as a powered primary or co-primary endpoint; most report adverse-event tables and leave the quality-of-life inference implicit, which is why the Kanwar pooled analysis carries more of the direct toxicity-comparison weight than any single trial [20]. The enhanced permeability and retention rationale is also less universal than early reviews suggested, with Golombek and colleagues and Sindhvani and colleagues both showing passive tumor accumulation varies substantially by and within tumor type, likely explaining why efficacy gains have been inconsistent even where toxicity gains have been reproducible [4,8]. And the nanorobotic component of this review's title remains the least evidenced part of the story: the control-theoretic and microrobotic literature is mechanistically exciting but has not produced a comparative human trial with a quality-of-life endpoint, so any claim specific to actively steered platforms is currently extrapolation rather than direct demonstration [5,6].

Two implications follow. New nanoparticle and nanorobotic trials should build validated quality-of-life instruments into their endpoint structure from the outset rather than relying on adverse-event tables and post hoc

inference [1,2,7]. And as nanorobotic mechanisms move toward first-in-human testing, the toxicity-sparing benchmark already set by passive platforms should be the comparator any added navigational complexity must justify [11,16].

9. Conclusion

Across ovarian, breast, and pancreatic cancer, the nanoparticle reformulations reviewed here consistently trade a modest or comparable change in tumor control for a meaningfully different, and generally more favorable, toxicity profile, and that toxicity reduction, expressed through validated instruments where used and through adverse-event and symptom data where not, is the strongest evidenced benefit of nanoparticle drug delivery in solid tumors to date [12,16,18,20]. The nanorobotic and actively targeted platforms that extend this logic further remain a preclinical and conceptual extension of a toxicity-sparing rationale already validated for passive and semi-active carriers rather than an independently demonstrated clinical benefit, and closing that gap will require trials that measure quality of life directly, powered for that purpose, as these more actively engineered systems reach patients [5,6,24].

10. Acknowledgements

The authors thank their respective institutions for providing the literature access and research infrastructure that supported this synthesis.

11. Funding

This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

12. Conflict of Interest

The authors declare no conflict of interest.

13. Author Contributions

Zhang X conceived the review and drafted the manuscript. Liu J performed the literature synthesis and prepared the

figures and tables. Huang H critically revised the manuscript for scientific content. All authors read and approved the final manuscript.

14. Ethics Statement

This article is a literature synthesis and did not involve new experiments on human participants or animals; no ethics approval was required.

15. Data Availability

No new data were generated for this review. All data discussed are available in the cited original publications.

16. References

1. Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *Journal of the National Cancer Institute*, 85(5): 365-376. DOI: [10.1093/jnci/85.5.365](https://doi.org/10.1093/jnci/85.5.365)
2. Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. *Journal of Clinical Oncology*, 11(3): 570-579. DOI: [10.1200/JCO.1993.11.3.570](https://doi.org/10.1200/JCO.1993.11.3.570)
3. Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R., Langer, R. (2007) Nanocarriers as an emerging platform for cancer therapy. *Nature Nanotechnology*, 2(12): 751-760. DOI: [10.1038/nnano.2007.387](https://doi.org/10.1038/nnano.2007.387)
4. Golombek, S.K., May, J.N., Theek, B., Appold, L., Drude, N., Kiessling, F., et al. (2018) Tumor targeting via EPR: strategies to enhance patient responses. *Advanced Drug Delivery Reviews*, 130: 17-38. DOI: [10.1016/j.addr.2018.07.007](https://doi.org/10.1016/j.addr.2018.07.007)
5. Cavalcanti, A., Freitas, R.A. (2005) Nanorobotics control design: a collective behavior approach for medicine. *IEEE Transactions on NanoBioscience*, 4(2): 133-140. DOI: [10.1109/tnb.2005.850469](https://doi.org/10.1109/tnb.2005.850469)
6. Erkoc, P., Yasa, I.C., Ceylan, H., Yasa, O., Alapan, Y., Sitti, M.

- (2019) Mobile microrobots for active therapeutic delivery. *Advanced Therapeutics*, 2(1): 1800064. DOI: [10.1002/adtp.201800064](https://doi.org/10.1002/adtp.201800064)
7. Herdman, M., Gudex, C., Lloyd, A., Janssen, M.F., Kind, P., Parkin, D., et al. (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Quality of Life Research*, 20(10): 1727-1736. DOI: [10.1007/s11136-011-9903-x](https://doi.org/10.1007/s11136-011-9903-x)
8. Sindhwani, S., Syed, A.M., Ngai, J., Kingston, B.R., Maiorino, L., Rothschild, J., et al. (2020) The entry of nanoparticles into solid tumours. *Nature Materials*, 19(5): 566-575. DOI: [10.1038/s41563-019-0566-2](https://doi.org/10.1038/s41563-019-0566-2)
9. Shi, J., Kantoff, P.W., Wooster, R., Farokhzad, O.C. (2017) Cancer nanomedicine: progress, challenges and opportunities. *Nature Reviews Cancer*, 17(1): 20-37. DOI: [10.1038/nrc.2016.108](https://doi.org/10.1038/nrc.2016.108)
10. Wicki, A., Witzigmann, D., Balasubramanian, V., Huwyler, J. (2015) Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. *Journal of Controlled Release*, 200: 138-157. DOI: [10.1016/j.jconrel.2014.12.030](https://doi.org/10.1016/j.jconrel.2014.12.030)
11. Barenholz, Y. (2012) Doxil - the first FDA-approved nano-drug: lessons learned. *Journal of Controlled Release*, 160(2): 117-134. DOI: [10.1016/j.jconrel.2012.03.020](https://doi.org/10.1016/j.jconrel.2012.03.020)
12. O'Brien, M.E.R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., et al. (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Annals of Oncology*, 15(3): 440-449. DOI: [10.1093/annonc/mdh097](https://doi.org/10.1093/annonc/mdh097)
13. Safra, T., Muggia, F., Jeffers, S., Tsao-Wei, D.D., Groshen, S., Lyass, O., et al. (2000) Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m². *Annals of Oncology*, 11(8): 1029-1033. DOI: [10.1023/a:1008365716693](https://doi.org/10.1023/a:1008365716693)
14. Gordon, A.N., Fleagle, J.T., Guthrie, D., Parkin, D.E., Gore, M.E., Lacave, A.J. (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. *Journal of Clinical Oncology*, 19(14): 3312-3322. DOI: [10.1200/JCO.2001.19.14.3312](https://doi.org/10.1200/JCO.2001.19.14.3312)
15. Krown, S.E., Northfelt, D.W., Osoba, D., Stewart, J.S. (2004) Use of liposomal anthracyclines in Kaposi's sarcoma. *Seminars in Oncology*, 31(6 Suppl 13): 36-52. DOI: [10.1053/j.seminoncol.2004.08.003](https://doi.org/10.1053/j.seminoncol.2004.08.003)
16. Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., et al. (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *Journal of Clinical Oncology*, 23(31): 7794-7803. DOI: [10.1200/JCO.2005.04.937](https://doi.org/10.1200/JCO.2005.04.937)
17. Kim, T.Y., Kim, D.W., Chung, J.Y., Shin, S.G., Kim, S.C., Heo, D.S., et al. (2004) Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. *Clinical Cancer Research*, 10(11): 3708-3716. DOI: [10.1158/1078-0432.ccr-03-0655](https://doi.org/10.1158/1078-0432.ccr-03-0655)
18. Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., et al. (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *New England Journal of Medicine*, 369(18): 1691-1703. DOI: [10.1056/NEJMoa1304369](https://doi.org/10.1056/NEJMoa1304369)
19. Wang-Gillam, A., Li, C.P., Bodoky, G., Dean, A., Shan, Y.S., Jameson, G., et al. (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. *The Lancet*, 387(10018): 545-557. DOI: [10.1016/S0140-6736\(15\)00986-1](https://doi.org/10.1016/S0140-6736(15)00986-1)
20. Kanwar, M.M., Noor, A., Rasool, T., Anjum, H.S., Ashraf, A., Rahman, A.U., Rehman, M.U. (2025) Meta-analysis of efficacy of nanoparticle-based chemotherapy compared to conventional chemotherapy in solid tumors.

Citation: Zhang X, Liu J, Huang H (2026) Impact of nanorobotic drug delivery on Quality of Life in Patients with solid tumors. *Ann Nanomed Nanotechnol*, 8(1): 01-06.

Insights-Journal of Health and Rehabilitation. DOI: [10.71000/rce00f58](https://doi.org/10.71000/rce00f58)

21. Bobo, D., Robinson, K.J., Islam, J., Thurecht, K.J., Corrie, S.R. (2016) Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. *Pharmaceutical Research*, 33(10): 2373-2387. DOI: [10.1007/s11095-016-1958-5](https://doi.org/10.1007/s11095-016-1958-5)
22. Anselmo, A.C., Mitragotri, S. (2016) Nanoparticles in the clinic. *Bioengineering & Translational Medicine*, 1(1): 10-29. DOI: [10.1002/btm2.10003](https://doi.org/10.1002/btm2.10003)
23. Anselmo, A.C., Mitragotri, S. (2019) Nanoparticles in the clinic: an update. *Bioengineering & Translational Medicine*, 4(3): e10143. DOI: [10.1002/btm2.10143](https://doi.org/10.1002/btm2.10143)
24. van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W.J.M., Lammers, T. (2019) Smart cancer nanomedicine. *Nature Nanotechnology*, 14(11): 1007-1017. DOI: [10.1038/s41565-019-0567-y](https://doi.org/10.1038/s41565-019-0567-y)

